Protecting Scientific Integrity and Public Policy Pronouncements on COVID-19

Michael McAleer

Advances in Decision Sciences, 2020, vol. 24, issue 1, 70-84

Abstract: The SARS-CoV-2 virus and the associated COVID-19 disease is a pandemic that has rocked the world in terms of public health and medical issues, business, economics and finance. Interesting and topical discussions regarding risk management of COVID-19 have been reported in leading business, economics, finance, and medical journals, as well as information and misinformation, intended or not, in the mass media. In this context, protecting the integrity of public policy pronouncements relating to the conduct and outcomes of scientific clinical trials. In terms of protecting the scientific integrity of clinical trials of COVID-19 patients, it is intentional to determine whether imperfectly collected data on clinical trials are more useful than having no data at all.

Keywords: COVID-19; SARS-CoV-2; scientific integrity; public policy pronouncements; medical research; business, economics and finance (search for similar items in EconPapers)
JEL-codes: D81 G32 H12 L82 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://iads.site/Protecting-Scientific-Integrity- ... ncements-on-COVID-19 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:aag:wpaper:v:24:y:2020:i:1:p:70-84

Access Statistics for this article

More articles in Advances in Decision Sciences from Asia University, Taiwan Contact information at EDIRC.
Bibliographic data for series maintained by Vincent Pan ().